AD	

Award Number: DAMD17-00-1-0452

TITLE: Role of c-myb in Breast Development and Cancer

PRINCIPAL INVESTIGATOR: Yen K. Lieu

E. Premkumar Reddy, Ph.D.

CONTRACTING ORGANIZATION: Temple University School of Medicine

Philadelphia, Pennsylvania 19140

REPORT DATE: June 2002

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Burdent Pagagement Reducing Project (704-0-188). Washington Head

Management and Budget, Paperwork Reduction Project	ct (0704-0188), washington, DO 20303				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND	PORT TYPE AND DATES COVERED		
	June 2002	Annual Summary	(15 May 2001 - 14 May 2002)		
4.TITLE AND SUBTITLE Role of c-myb in Breast	Development and Cance	r	5. FUNDING NUNUMBER DAMD17-00-1-0452		
6. AUTHOR(S)					
Yen K. Lieu					
E. Premkumar Reddy,	Ph.D.				
7. PERFORMING ORGANIZATION NAM			8. PERFORMING ORGANIZATION REPORT NUMBER		
Temple University Sc	hool of Medicine				
Philadelphia, Pennsy	lvania 19140				
email - yenklieu@hotma	il.com				
-					
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES))	10. SPONSORING / MONITORING		
			AGENCY REPORT NUMBER		
U.S. Army Medical Research and M Fort Detrick, Maryland 21702-501					
-					
-					
Fort Detrick, Maryland 21702-501:					
Fort Detrick, Maryland 21702-501: 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY S	2 BTATEMENT		12b. DISTRIBUTION CODE		
Fort Detrick, Maryland 21702-501:	2 BTATEMENT	imited	12b. DISTRIBUTION CODE		
Fort Detrick, Maryland 21702-501: 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY S	STATEMENT ease; Distribution Unl	imited	12b. DISTRIBUTION CODE		

c-myb, along with A-myb and B-myb, belongs to the myb gene family which codes for nuclear proteins that bind DNA in a sequence-specific manner and function as regulators of transcription. There is a large body of evidence to suggest a role for c-myb in breast development and cancer c-myb is highly expressed in all estrogen receptor positive breast tumors and cell lines. In addition, our in situ hybridization studies show that c-myb is expressed at high levels in ductal cells from breast tissues of virgin and pregnant mice. To address the role of c-myb in mammary development and cancer, we propose to create c-myb conditional knockout mice where the expression of this gene is interrupted specifically in the mammary gland using the Cre-lox system. We are in the process of generating chimeric mice by injecting our conditional c-myb deletion ES cells into blastocysts of C57 X CBA pseudopregnant mice. Founder mice will be identified and bred to homozygosity for carrying conditional c-myb deletion alleles and, additionally, to bear either a MMTV-cre or a WAP-cre transgene. The generation of breast-specific c-myb conditional knockout mice will afford us the opportunity to dissect the role of c-myb in normal breast development and cancer.

14. SUBJECT TERMS breast cancer, c-myb, estrogen rceptor, ductal proliferation			15. NUMBER OF PAGES 8
			16. PRICE CODE
17. SECURITY CLASSIFICATION	18. SECURITY CLASSIFICATION	19. SECURITY CLASSIFICATION	20. LIMITATION OF ABSTRACT
OF REPORT Unclassified	OF THIS PAGE Unclassified	OF ABSTRACT	Unlimited
Unclassified	Unclassified	Unclassified	

Table of Contents

Cover1	
SF 2982	
Introduction4	
Body4-7	7
Key Research Accomplishments7	
Reportable Outcomes7	
Conclusions7-8	;
References8	
Appendices8	

Introduction

The development of breast cancer is a multistage process involving alterations in tumor suppressor genes and oncogenes. Overexpression of c-myb oncogene has been reported in human estrogen receptor positive (ER+) tumors and ER+ mammary carcinoma cell lines (1,2,3, also our unpublished data). In fact, cumulative data have shown c-myb to be one of the most frequently altered genes in breast cancer (1,4,5). In addition, recent data have shown a correlation between c-myb oncogene amplification and hereditary BRCA1 breast cancer (6). c-myb, along with A-myb and B-myb, belongs to the myb gene family which codes for nuclear proteins that bind DNA in a sequence-specific manner and function as regulators of transcription (7,8).

c-myb is predominantly expressed in hematopeoietic cells and its essential role for the proliferative potential of these cells has been well established (9). Homozygous null c-myb mutant mice die in utero due to defects in fetal hepatic hematopoiesis (10). However, the role of c-myb in breast development and breast cancer is beginning to emerge only recently. The first evidence that implicated a role for c-myb in breast tumors came from the observation that this gene is highly expressed in all estrogen receptor positive (ER+) breast tumors and mammary carcinoma cell lines (1,2,3, also our unpublished data). In addition, expression of a dominant negative mutant of the c-myb in ER+ breast carcinomas was found to result in their growth arrest and loss of tumorigenicity (our unpublished observations). To determine whether c-myb gene plays a role in breast development, we examined the pattern of expression of this gene in breast tissues derived from virgin, pregnant and lactacting mice. *In situ* hybridization studies show that c-myb is expressed at high levels in ductal cells derived from breast tissues of virgin and pregnant mice but is down-regulated in breast tissue of lactating mice. This observation combined with the observation that c-myb is highly expressed in ER+ breast tumor cells suggests that this gene might play a critical role in estrogen-mediated ductal cell proliferation.

Body

The main objective of my application is to study the effects of c-myb gene deletion on breast development using the embryonic stem (ES) cell technology and the Cre-lox system.

During my first grant year, I was unable to produce any type II conditional c-myb deletion ES clones but did learn the techniques for working with ES cells. This past year, I was able to isolate one type II ES clone RW4/38/33 from one of the recombinant ES cell clones that had been passed on to me. However, the karyotype of RW4/38/33 was abnormal. The other recombinant ES clones that I inherited either were karyotypically abnormal or could not yield type I systemic or II conditional c-myb deletion ES cells. So, I had to make new recombinant c-myb ES cell clones by electroporating the linearized targeting vector into RW4 ES cells, selecting with G418, and screening by Southern blotting with exon 9A probe after StuI digestion. After screening 300 clones, I did not get any true positive recombinant ES clones except for many false positive recombinant clones due to incomplete digestion by StuI restriction enzyme.




Figure 1: The modified c-myb targeting construct contains an extra BamHI restriction site between the tk and Neo genes.




Figure 2: Agarose gel comparing the restriction banding patterns between the old and new targeting vector. Notice the new vector has an extra band as indicated by the arrow mark.

With the help of another lab member, I decided to modify the original targeting vector by

simply inserting a BamHI linker in the region between the thymidine kinase gene and the neomycin resistant gene (Fig 1). As shown in figure 2, the restriction band patterns on the agarose gels were the same for the new and old targeting vectors for all enzymes examined except BamHI where the new vector yielded an extra band as expected. This modified targeting vector enables efficient screening of c-myb recombinant clones by digestion with BamHI and using a probe upstream of exon2.




Figure 3: Southern blot analysis of the c-myb recombinant clones.

As shown on figure 3, when I introduced the new vector into both R1 and RW4 ES cells and after screening 900 clones, I was able to isolate 9 bona fide positive recombinant clones. I carried out cell spreading experiments to determine which of the 9 recombinant clones have normal chromosome number. R1/51, R1/62, R1/354, RW4/23, RW4/242, R1/58 and R1/161 have the normal murine 40 chromosomes and the first 5 recombinant clones were sent for karyotyping analysis by Dr. Joseph Testa of Fox Chase Cancer Center, Philadelphia, PA. Results showed that only R1/51, R1/62 and RW4/23 have normal karyotype. Various concentrations of P1 bacterial recombinase cre were electroporated into these three normal ES clones. As shown on figure 3, a total of 6 type II conditional c-myb ES deletions were isolated, 3 from R1/51 and 3 from RW4/23 recombinant c-myb clones. Two type II ES clones from each of the two first transfectants were sent for karyotyping analysis by Dr Chih-Lin Hsieh of the University of Southern California and all 4 type II deletion ES clones, R1/51.29/5, R1/51.18/82, RW4/23/47 and RW4/23/62, have normal karyotype. I am in the process of generating chimeric mice by having two of the four type II conditional c-myb deletion ES clonal cells, R1/51.18/82 and RW4/23/47, microinjected into blastocysts of C57B/L6 X CBA pseudopregnant mice by Dr.

Thom Saunders of University of Michigan Transgenic Core Facility. Once I get chimeric mice, founder mice will be identified and bred to carry two copies of the conditional c-myb deletion alleles and also to bear either a MMTV-cre or a WAP-cre transgene.




Figure 4: Southern blot analysis showing the type II conditional c-myb deletion clones. 11.5 Kb-wt, 10.6 Kb-type I systemic c-myb deletion, 9.8 Kb-recombinant and 7.8 Kb-type II conditional c-myb deletion.

Key Research Accomplishments

- Construction of an improved c-myb targeting vector for efficient screening of recombinant clones.
- Isolation of at least 3 normal recombinant c-myb ES clones.
- Production of at least 4 normal type II conditional c-myb deletion ES clones.

Reportable Outcomes

None

Conclusions

We have isolated at least 3 normal recombinant c-myb ES clones using a modified c-myb targeting vector that we have constructed. After introduction of the P1 bacterial recombinase cre into these recombinant clones, we have obtained at least 4 normal type II conditional c-myb deletion ES clones which are currently being microinjected to produce chimera mice. We believe the generation of breast-specific c-myb conditional knockout mice will provide an invaluable model for dissecting the role of c-myb in normal development as well as gain insight

into the role of its aberrant expression in breast cancer. Furthermore, we believe that a detailed molecular understanding of how c-myb contributes to tumor progression is of major importance for future therapy.

References

- 1. Cline MJ, Battifora H, Yokota J. Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. J Clin Oncol. 1987 Jul;5(7):999-1006.
- 2. Guerin M, Sheng ZM, Andrieu N, Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene. 1990 Jan;5(1):131-5.
- 3. Gudas JM, Klein RC, Oka M, Cowan KH. Posttranscriptional regulation of the c-myb proto-oncogene in estrogen receptor-positive breast cancer cells. Clin Cancer Res. 1995 Feb;1(2):235-43.
- 4. Biunno I, Pozzi MR, Pierotti MA, Pilotti S, Cattoretti G, Della Porta G. Structure and expression of oncogenes in surgical specimens of human breast carcinomas. Br J Cancer. 1988 May;57(5):464-8.
- 5. Zhou DJ, Ahuja H, Cline MJ. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene. 1989 Jan;4(1):105-8.
- 6. Kauraniemi P, Hedenfalk I, Persson K, Duggan DJ, Tanner M, Johannsson O, Olsson H, Trent JM, Isola J, Borg A. MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res. 2000 Oct 1;60(19):5323-8.
- 7. Sakura H, Kanei-Ishii C, Nagase T, Nakagoshi H, Gonda TJ and Ishii S. Delineation of three functional domains of the transcriptional activator encoded by the c-myb protooncogene. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5758-62.
- 8. Weston K and Bishop JM. Transcriptional Activation by the V-myb Oncogene and Its Cellular Progenitor, c-myb. Cell 1989 58: 85.
- 9 Golay J., Capucci A, Arsura M, Castellano M, Rizzo V, Introna M. Expression of c-myb and B-myb, but not A-myb, correlates with proliferation in human hematopoietic cells. Blood. 1991 Jan 1;77(1):149-58.
- 10. Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner CM, Miller TA, Pietryga DW, Scott WJ Jr, Potter SS. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell. 1991 May 17;65(4):677-89.